html5-img
1 / 15

April 2008, Belfast

BHIVA 14th Annual Conference. April 2008, Belfast. Belfast Waterfront Hall. BHIVA 14th Annual Conference. 500 delegates 200 Poster presentations 30 oral abstracts 10 Satellite symposiums 5 Plenary sessions 3 big workshops

star
Download Presentation

April 2008, Belfast

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. BHIVA 14th Annual Conference April 2008, Belfast Belfast Waterfront Hall

  2. BHIVA 14th Annual Conference • 500 delegates • 200 Poster presentations • 30 oral abstracts • 10 Satellite symposiums • 5 Plenary sessions • 3 big workshops • Presentation of awards for 3 best abstracts of the conference by the Mayor of Belfast.

  3. Relevant abstracts • Immunotherapy while delaying HAART • 350 CD4 threshold for starting therapy • Protease Inhibitors monotherapy • Diagnosing the undiagnosed • Ageing of the PLH population • HIV treatment adherence for adolescents • Community HIV treatment adherence support • The importance of home delivery for ARVs

  4. Diagnosing the undiagnosed • Targeted prevention • Communities • Primary Care HIV testing • Background • CDC – routine testing of 13-64 olds to reduce late presentations • Methods • Past diagnosed prevalence for MSM and HS MSM - 0.25% prevalence and black women 2%

  5. Diagnosing the undiagnosed • Conclusion • Localised approach of targeting offers HIV testing based on simple risk assessments. • It allows local patient acceptability, setting appropriateness and partner notification.

  6. Protease Inhibitors mono-therapyThe KIMODO Study • Kaletra (Lopinavir + Ritonavir) monotherapy • Kaletra + Sustiva/Neviralpine • No significant difference between the two • Benefits • Less toxicity • Better adherence • Better resistance profile

  7. Immunotherapy while delaying HAART

  8. 350 CD4 threshold for starting therapy

  9. Ageing of the PLH population • Cardiovascular disease • Diabetes • Dementia • Physical weakness • Care for elderly • Mobility • Sensory impairment • Living will/Funeral arrangements…

  10. New Drugs • Celsentri (Maraviroc) – CCR5 antagonist • Isentress (Raltegravir) – Integrase inhibitor • Atripula od (Tenofovir+ Emtrica +Sustiva)

More Related